Bodzek Piotr, Partyka Robert, Damasiewicz-Bodzek Aleksandra
Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland.
J Ovarian Res. 2014 Mar 11;7:30. doi: 10.1186/1757-2215-7-30.
The aim of this study was to evaluate the concentrations of IgG antibodies against Hsp60 and Hsp65 in sera of patients with ovarian cancer at various stages of clinical progress and for different histopathological types of disease.
Serum samples from 149 patients with ovarian carcinoma and 80 healthy women were investigated. The concentrations of anti-Hsp60 and anti-Hsp65 antibodies were determined using the enzyme-linked immunosorbent assay technique.
The mean concentrations of anti-Hsp60 and anti-Hsp65 antibodies in the patients with ovarian cancer did not differ significantly from the mean levels in healthy women. Analysis in relation to the clinical progression stage showed that the concentrations of these antibodies were higher when the neoplastic process was less advanced and at early stages significantly higher than in control group. Mean concentrations of both antibodies were not significantly different in relation to the histological type of the ovarian cancer. The use of chemotherapy as a primary anticancer treatment did not cause a significant change in the concentration of anti-Hsp60 antibodies, but the mean level of anti-Hsp65 after this treatment was significantly higher than in control group.
The immunological response to Hsp60/65 is increased in early clinical stages of ovarian cancer and the level of anti-hsp60/65 antibodies may be then a helpful diagnostic marker. Even antibodies against highly homologous Hsps may be cross-reactive only partially and differ by some functional properties.
本研究旨在评估处于临床进展不同阶段以及患有不同组织病理学类型疾病的卵巢癌患者血清中抗Hsp60和抗Hsp65 IgG抗体的浓度。
对149例卵巢癌患者和80例健康女性的血清样本进行研究。采用酶联免疫吸附测定技术测定抗Hsp60和抗Hsp65抗体的浓度。
卵巢癌患者中抗Hsp60和抗Hsp65抗体的平均浓度与健康女性的平均水平无显著差异。与临床进展阶段相关的分析表明，当肿瘤进程较不严重时，这些抗体的浓度较高，且在早期显著高于对照组。两种抗体的平均浓度在卵巢癌组织学类型方面无显著差异。以化疗作为主要抗癌治疗手段并未导致抗Hsp60抗体浓度发生显著变化，但该治疗后抗Hsp65的平均水平显著高于对照组。
卵巢癌临床早期对Hsp60/65的免疫反应增强，此时抗Hsp60/65抗体水平可能是一种有用的诊断标志物。即使是针对高度同源热休克蛋白的抗体也可能仅部分交叉反应，并且在某些功能特性上存在差异。
